Nifuroxazide, 200 mg capsules 14 pcs

Pharmacotherapeutic group: Antimicrobial agent – nitrofuran

ATC code: A07AX03

Pharmacodynamics:

Nifuroxazide is an antimicrobial agent derived from nitrofuran. It blocks activity of dehydrogenases and inhibits respiratory chain tricarboxylic acid cycle and several other biochemical processes in microbial cell. It destroys the membrane of the microbial cell and decreases production of toxins by microorganisms.

Highly active against Campylobacter jejuni Escherichia coli Salmonella spp Shigella spp; Clostridium perfringens Vibrio cholerae pathogenic Vibrions and Vibrio parahaemolytique Staphylococcus spp.

Low sensitivity to nifuroxazide: Citrobacter spp Enterobacter cloacae and Proteus indologenes.

Resistant to nifuroxazide: Klebsiella spp Proteus mirabilis Providencia spp. Pseudomonas spp.

Nifuroxazide does not disturb the balance of intestinal microflora. In acute bacterial diarrhea it restores intestinal eubiosis. In case of infection with enterotropic viruses it prevents development of bacterial superinfection.

Pharmacokinetics:

Nifuroxazide is practically not absorbed from digestive tract after oral administration and its antibacterial effect is produced only in intestinal lumen. Nifuroxazide is excreted by the intestine: 20% in unchanged form and the remaining amount of nifuroxazide – chemically changed.

Indications

Acute bacterial diarrhea occurring without worsening the general condition of increased body temperature and intoxication.

Pharmacological effect

Pharmacotherapeutic group: Antimicrobial agent – nitrofuran

ATX code: A07AX03

Pharmacodynamics:

Nifuroxazide is an antimicrobial agent derived from nitrofuran. Blocks the activity of dehydrogenases and inhibits the respiratory chain, the cycle of tricarboxylic acids and a number of other biochemical processes in the microbial cell. Destroys the microbial cell membrane and reduces the production of toxins by microorganisms.

Highly active against Campylobacter jejuni Escherichia coli Salmonella spp Shigella spp; Clostridium perfringens Vibrio cholerae pathogenic Vibrions and Vibrio parahaemolytique Staphylococcus spp.

Weakly sensitive to nifuroxazide: Citrobacter spp Enterobacter cloacae and Proteus indologenes.

Resistant to nifuroxazide: Klebsiella spp Proteus mirabilis Providencia spp. Pseudomonas spp.

Nifuroxazide does not disturb the balance of intestinal microflora. In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokinetics:

After oral administration, nifuroxazide is practically not absorbed from the digestive tract and exerts its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestines: 20% unchanged and the remaining amount of nifuroxazide is chemically modified.

Special instructions

When treating diarrhea, rehydration therapy must be carried out simultaneously with nifuroxazide therapy.

In case of bacterial diarrhea with signs of systemic damage (deterioration in general condition, increased body temperature, symptoms of intoxication or infection), you should consult a doctor to decide on the use of systemic antibacterial drugs.

If symptoms of hypersensitivity occur (shortness of breath, rash, itching), you should stop taking the drug.

Alcohol consumption is prohibited during therapy.

The maximum daily dose of the drug (800 mg) contains 0023 XE.

Impact on the ability to drive vehicles. Wed and fur.:

The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Nifuroxazide

Composition

1 capsule 200 mg:

Active ingredient: nifuroxazide – 200.00 mg.

Excipients: sucrose – 70.00 mg; microcrystalline cellulose – 41.50 mg; corn starch – 35.00 mg; magnesium stearate – 3.50 mg.

Composition of the capsule body: quinoline yellow dye – 0.7500%; sunset yellow dye – 0.0059%; titanium dioxide – 2.0000%; gelatin – up to 100%. Composition of the capsule cap: quinoline yellow dye – 0.7500%; sunset yellow dye – 0.0059%; titanium dioxide – 2.0000%; gelatin – up to 100%.

Pregnancy

In animal studies, no teratogenic effect was detected. However, as a precaution, taking nifuroxazide during pregnancy is not recommended.

During the lactation period, it is possible to continue breastfeeding in case of a short course of treatment with the drug. You should consult your doctor.

Contraindications

– Hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug;

– fructose intolerance, glucose-galactose malabsorption syndrome or sucrase and isomaltase deficiency;

– pregnancy;

– children under 3 years of age.

Side Effects

Allergic reactions (skin rash, urticaria, angioedema, anaphylactic shock). If any of the side effects indicated in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Concomitant use with drugs that cause the development of disulfiram-like reactions with drugs that depress the function of the central nervous system is not recommended.

If you are taking other medications (including over-the-counter medications), consult your doctor before using Nifuroxazide.

Overdose

Overdose symptoms are not described. Treatment is symptomatic.

Storage conditions

In a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life

3 years. Do not use the drug after the expiration date.

Manufacturer

Ozon, Russia